Patents Assigned to TaiGen Biopharmaceuticals Co.(Beijing), Ltd.
  • Amorphous solid dispersion formulation
    Patent number: 11872224
    Abstract: The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: January 16, 2024
    Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co. (Beijing), Ltd.
    Inventors: Chi-Feng Yen, Fang-Wei Tien
  • Stereoselective synthesis of intermediate for preparation of heterocyclic compound
    Patent number: 11639349
    Abstract: Provided is a stereoselective synthesis of an intermediate for the preparation of the heterocyclic derivative as a Cap-dependent endonuclease inhibitor. The synthesis process has the advantages of simple operation, higher yield and relatively controllable steroselectivity, such that it is suitable for large-scale production.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: May 2, 2023
    Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co.(Beijing), Ltd.
    Inventors: Wen-Chang Chen, Han-Pei Hsu, Shan-Yen Chou, Shih-Chieh Chuang, Chi-Feng Yen